Trial · NCT04348513
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of weaning from cardiorespiratory support | 30 days | The primary objective of the study is to determine whether the administration of intravenous triiodothyronine in ICU patients diagnosed with pulmonary infection due to COVID-19 facilitates weaning from cardiorespiratory support compared to placebo. Successful weaning is defined as no requirement for ventilatory support after extubation (mechanical support) or support from ECMO for 48 hours. The primary objective will be measured as percentage of patients successfully weaned after 30 days of follow-up. |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by continuous blood pressure measurements (systolic BP in mmHg) |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by continuous blood pressure measurements (diastolic BP in mmHg) |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by continuous blood pressure measurements (mean BP in mmHg) |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by the number of participants with use of inotropic and vasoactive drugs |
| Secondary | Assessment of pulmonary function | 30 days | Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of oxygen in mmHg) |
| Secondary | Assessment of pulmonary function | 30 days | Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of carbon dioxide in mmHg) |
| Secondary | Assessment of pulmonary function | 30 days | Pulmonary function will be assessed by arterial measurement of lactate levels (in mmol/L) |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in aspartate aminotransferase (AST in IU/L) will be measured. |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in alanine aminotransferase (ALT in IU/L) will be measured. |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in gamma-glutamyl transpeptidase (γ-GT in IU/L) will be measured. |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in bilirubin in mg/dL will be measured. |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in fibrinogen in mg/dL will be measured. |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in d-dimers in ng/ml will be measured. |
| Secondary | Assessment of renal function | 30 days | Urine volume during 24 hours (in ml) will be recorded. |
| Secondary | Assessment of renal function | 30 days | Changes in urea (in mg/dL) will be recorded. |
| Secondary | Assessment of renal function | 30 days | Changes in uric acid (in mg/dL) will be recorded. |
| Secondary | Assessment of renal function | 30 days | Changes in creatinine (in mg/dL) will be recorded. |
| Secondary | Assessment of cardiac function | 30 days | Echocardiographic assessment of cardiac left ventricular ejection fraction (LVEF, %) |
| Secondary | Assessment of cardiac injury | 30 days | Measurements of cardiac troponin I (in μg/L) will be used to assess myocardial injury |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04348513/registered